Keytruda (pembrolizumab) continues to keep sales looking very healthy at US pharma giant Merck & Co (NYSE: MRK) as revenue from the immuno-oncology treatment went up by nearly $1 billion compared to the second quarter of 2018.
A remarkable 58% jump in sales of the drug, or 63% at constant currencies, along with strong demand for the company’s vaccines, and a 41% increase in revenue from the Chinese market, helped Merck’s total sales to grow by 12% to $11.76 billion.
The Keytruda and total sales figures beat expectations, as they did for the group’s earnings during the quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze